[Federal Register Volume 75, Number 243 (Monday, December 20, 2010)]
[Rules and Regulations]
[Pages 79295-79296]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 2010-31870]
=======================================================================
-----------------------------------------------------------------------
DEPARTMENT OF HEALTH AND HUMAN SERVICES
Food and Drug Administration
21 CFR Parts 510 and 524
[Docket No. FDA-2010-N-0002]
New Animal Drugs; Mupirocin
AGENCY: Food and Drug Administration, HHS.
ACTION: Final rule.
-----------------------------------------------------------------------
SUMMARY: The Food and Drug Administration (FDA) is amending the animal
drug regulations to reflect approval of an abbreviated new animal drug
application (ANADA) filed by Taro Pharmaceuticals U.S.A., Inc. The
ANADA provides for veterinary prescription use of mupirocin ointment
for the treatment of bacterial skin infections in dogs.
DATES: This rule is effective December 20, 2010.
FOR FURTHER INFORMATION CONTACT: John K. Harshman, Center for
Veterinary
[[Page 79296]]
Medicine (HFV-170), Food and Drug Administration, 7500 Standish Pl.,
Rockville, MD 20855, 240-276-8197, e-mail: [email protected].
SUPPLEMENTARY INFORMATION: Taro Pharmaceuticals U.S.A., Inc., 3 Skyline
Dr., Hawthorne, NY 10532, filed ANADA 200-457 that provides for
veterinary prescription use of Mupirocin Ointment USP, 2% for the
treatment of bacterial skin infections in dogs. Taro Pharmaceuticals
U.S.A., Inc.'s Mupirocin Ointment USP, 2% is approved as a generic copy
of Pfizer, Inc.'s BACTODERM Ointment approved under NADA 140-839. The
ANADA is approved as of November 29, 2010, and the regulations are
amended in 21 CFR 524.1465 to reflect the approval.
In addition, Taro Pharmaceuticals U.S.A., Inc., has not been
previously listed in the animal drug regulations as a sponsor of an
approved application. Accordingly, the tables in 21 CFR 510.600(c) are
being amended to add entries for this firm.
In accordance with the freedom of information provisions of 21 CFR
part 20 and 21 CFR 514.11(e)(2)(ii), a summary of safety and
effectiveness data and information submitted to support approval of
this application may be seen in the Division of Dockets Management
(HFA-305), Food and Drug Administration, 5630 Fishers Lane, rm. 1061,
Rockville, MD 20852, between 9 a.m. and 4 p.m., Monday through Friday.
The Agency has determined under 21 CFR 25.33 that this action is of
a type that does not individually or cumulatively have a significant
effect on the human environment. Therefore, neither an environmental
assessment nor an environmental impact statement is required.
This rule does not meet the definition of ``rule'' in 5 U.S.C.
804(3)(A) because it is a rule of ``particular applicability.''
Therefore, it is not subject to the congressional review requirements
in 5 U.S.C. 801-808.
List of Subjects
21 CFR Part 510
Administrative practice and procedure, Animal drugs, Labeling,
Reporting and recordkeeping requirements.
21 CFR Part 524
Animal drugs.
Therefore, under the Federal Food, Drug, and Cosmetic Act and under
authority delegated to the Commissioner of Food and Drugs and
redelegated to the Center for Veterinary Medicine, 21 CFR parts 510 and
524 are amended as follows:
PART 510--NEW ANIMAL DRUGS
0
1. The authority citation for 21 CFR part 510 continues to read as
follows:
Authority: 21 U.S.C. 321, 331, 351, 352, 353, 360b, 371, 379e.
0
2. In Sec. 510.600, in the table in paragraph (c)(1) alphabetically
add an entry for ``Taro Pharmaceuticals U.S.A., Inc.''; and in the
table in paragraph (c)(2) numerically add an entry for ``051672'' to
read as follows:
Sec. 510.600 Names, addresses, and drug labeler codes of sponsors of
approved applications.
* * * * *
(c) * * *
(1) * * *
------------------------------------------------------------------------
Drug labeler
Firm name and address code
------------------------------------------------------------------------
* * * * *
Taro Pharmaceuticals U.S.A., Inc., 3 Skyline Dr., 051672
Hawthorne, NY 10532....................................
* * * * *
------------------------------------------------------------------------
(2) * * *
------------------------------------------------------------------------
Drug labeler code Firm name and address
------------------------------------------------------------------------
* * * * *
051672........................... Taro Pharmaceuticals U.S.A., Inc., 3
Skyline Dr., Hawthorne, NY 10532.
* * * * *
------------------------------------------------------------------------
PART 524--OPHTHALMIC AND TOPICAL DOSAGE FORM NEW ANIMAL DRUGS
0
3. The authority citation for 21 CFR part 524 continues to read as
follows:
Authority: 21 U.S.C. 360b.
Sec. 524.1465 [Amended]
0
4. In paragraph (b) of Sec. 524.1465, remove ``Nos. 000069 and
025463'' and in its place add ``Nos. 000069, 025463, and 051672''.
Dated: December 10, 2010.
Bernadette Dunham,
Director, Center for Veterinary Medicine.
[FR Doc. 2010-31870 Filed 12-17-10; 8:45 am]
BILLING CODE 4160-01-P